Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Financial writer recommends buying ARK Genomic Revolution ETF (ARKG) for potential growth in 2025. Explore more here.

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...